Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) sets new 12-month low at $18.16

0

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) the stock price hit a new 52-week low on Wednesday. The company traded as low as $18.16 and last traded at $18.18, with volume at 3591 shares. The stock had previously closed at $18.31.

Changes to analyst ratings

A number of research companies have weighed in on FMS recently. DZ Bank reduced shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Friday, July 29 research report. JPMorgan Chase & Co. cut its price target on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.58) to €23.00 ($23.71) in a research report released on Monday. Truist Financial lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “holding” rating for the company in a Wednesday 22 research report. June. UBS Group reduced shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a Friday, July 29 research report. Finally, Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from an “underperforming” rating to a “buy” rating and raised its price target for the company from $30.30 to $33.70 in a Monday, June 27 research report. One research analyst rated the stock with a sell rating, seven assigned a hold rating and four gave the stock a buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $49.01.

Pricing performance of Fresenius Medical Care AG & Co. KGaA

The stock’s fifty-day moving average price is $24.60 and its two-hundred-day moving average price is $29.72. The company has a market capitalization of $10.81 billion, a price-to-earnings ratio of 11.75, a growth price-to-earnings ratio of 0.85 and a beta of 1.02. The company has a current ratio of 1.26, a quick ratio of 0.93 and a debt ratio of 0.51.

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) last reported quarterly earnings data on Wednesday, May 4. The company reported earnings per share of $0.38 for the quarter, beating consensus analyst estimates of $0.30 by $0.08. Fresenius Medical Care AG & Co. KGaA achieved a net margin of 4.42% and a return on equity of 6.72%. The company posted revenue of $5.10 billion for the quarter, versus analyst estimates of $4.97 billion. Equity research analysts expect Fresenius Medical Care AG & Co. KGaA to post EPS of 1.78 for the current year.

Institutional investors weigh in on Fresenius Medical Care AG & Co. KGaA

Several hedge funds and other institutional investors have been buying and selling stocks recently. US Bancorp DE increased its stake in Fresenius Medical Care AG & Co. KGaA by 17.4% during the second quarter. US Bancorp DE now owns 15,767 shares of the company worth $393,000 after acquiring 2,335 additional shares in the last quarter. Creative Financial Designs Inc. ADV increased its stake in Fresenius Medical Care AG & Co. KGaA by 98.0% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 3,960 shares of the company worth $99,000 after acquiring 1,960 additional shares in the last quarter. Crossmark Global Holdings Inc. increased its stake in Fresenius Medical Care AG & Co. KGaA by 3.7% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 47,979 shares of the company worth $1,197,000 after acquiring 1,691 additional shares last quarter. National Bank of Canada FI increased its stake in Fresenius Medical Care AG & Co. KGaA by 11,054.0% during the 2nd quarter. National Bank of Canada FI now owns 16,731 shares of the company worth $417,000 after acquiring 16,581 additional shares last quarter. Finally, Wulff Hansen & CO. increased its stake in Fresenius Medical Care AG & Co. KGaA by 37.2% during the 2nd quarter. Wulff Hansen & CO. now owns 14,832 shares of the company worth $370,000 after acquiring 4,018 additional shares in the last quarter. 4.73% of the shares are currently held by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Recommended Stories



Get news and reviews for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s free daily email newsletter .

Share.

Comments are closed.